Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31342675 | 0.86 | ALDH1A1 (0.56) | ALDH1A1LMNASMN1; SMN2MAPTGAA | |
| SCHEMBL22028444 | 0.85 | SIRT6 (0.61) | ALDH1A1LMNASIRT6SMN1; SMN2MAPT | |
| SCHEMBL25369950 | 0.84 | ALDH1A1 (0.44) | ALDH1A1LMNASIRT6SMN1; SMN2MAPT | |
| SCHEMBL22942876 | 0.84 | HTT (0.55) | ALDH1A1LMNASMN1; SMN2MAPTHTT | |
| SCHEMBL2203183 | 0.84 | MAPT (0.50) | ALDH1A1LMNASIRT6SMN1; SMN2MAPT | |
| SCHEMBL7947767 | 0.82 | ALDH1A1 (0.41) | ALDH1A1LMNASMN1; SMN2MAPTHTT | |
| SCHEMBL25368911 | 0.82 | ALDH1A1 (0.42) | ALDH1A1LMNASIRT6SMN1; SMN2MAPT | |
| SCHEMBL2206009 | 0.82 | TDP1 (0.47) | ALDH1A1LMNASIRT6SMN1; SMN2MAPT | |
| SCHEMBL24327504 | 0.81 | SIRT6 (0.56) | ALDH1A1LMNASIRT6SMN1; SMN2MAPT | |
| SCHEMBL23759668 | 0.81 | SIRT6 (0.47) | ALDH1A1LMNASIRT6SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| CN-116323580-A | Conjugated degradation (EGFR) of EGFR inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022012622-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| EP-2601186-A2 | 4-(1H-INDOL-3-YL)-PYRIMIDINES AS ALK INHIBITORS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8461170-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-06-11 | — | — | US | disclosed |
| WO-2012017239-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | ALDH1A1 3281/4885LMNA 4230/4885SIRT6 2858/4885 |
| US-20120028924-A1 | CHEMICAL COMPOUNDS | ALK, BRAF, ABL1 | ALDH1A1 214/4885LMNA 1889/4885SIRT6 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.